Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Tuning Up Part D Amid Drug Pricing Debate; MedPAC Likely To Urge More Flexibility For Plans Setting Formularies

This article was originally published in RPM Report

Executive Summary

The Medicare Payment Advisory Committee (MedPAC) will be moving forward with specific recommendations to improve prescription drug provisions under Part D and Part B – but is not ready to take the lead on policy development addressing prescription drug prices overall.

Advertisement

Related Content

340B Drug Discount Program Hits A Turning Point, But In Which Direction?

Topics

Advertisement
UsernamePublicRestriction

Register

PS079802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel